{"filing":{"accession_number":"0001104659-26-094886","cik":"0001287098","ticker":"MXCT","company_name":"MAXCYTE, INC.","form":"8-K","filing_date":"2026-08-12","report_date":"2026-08-12","primary_document":"mxct-20260812x8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1287098/000110465926094886/mxct-20260812x8k.htm"},"events":[{"id":27215,"run_id":24788,"accession_number":"0001104659-26-094886","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.97,"summary":"MaxCyte issued a press release on August 12, 2026 announcing its financial results for the quarter ended June 30, 2026, disclosing total revenue of $7.3 million, net loss of $8.9 million, and full-year 2026 guidance of $30–$32 million in revenue. The release includes unaudited condensed consolidated financial statements and management commentary on strategic developments including the Genentech partnership and SPL portfolio progress.","company_name":"MAXCYTE, INC.","ticker":"MXCT","filing_date":"2026-08-12","form":"8-K","submitted_at":null,"items":[{"id":28639,"accession_number":"0001104659-26-094886","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"MaxCyte issued a press release on August 12, 2026 announcing its financial results for the quarter ended June 30, 2026, disclosing total revenue of $7.3 million, net loss of $8.9 million, and full-year 2026 guidance. This is a standard quarterly earnings release filed under Item 2.02 with the press release attached as Exhibit 99.1, accompanied by unaudited condensed consolidated financial statements (balance sheet, statements of operations, and cash flows).","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T20:18:59.621548+00:00","company_name":"","ticker":null,"filing_date":""},{"id":28640,"accession_number":"0001104659-26-094886","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The Item 7.01 disclosure furnishes MaxCyte's second quarter 2026 financial results press release (Exhibit 99.1), which reports total revenue of $7.3 million, net loss of $8.9 million, and full-year 2026 guidance of $30–$32 million in revenue. This is a standard quarterly earnings release with detailed financial statements and management commentary, meeting the definition of earnings_release. The material nature is confirmed by the company's reiteration of full-year guidance and discussion of strategic developments (Genentech partnership, SPL portfolio progress).","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T20:18:59.621548+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":28639,"accession_number":"0001104659-26-094886","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"MaxCyte issued a press release on August 12, 2026 announcing its financial results for the quarter ended June 30, 2026, disclosing total revenue of $7.3 million, net loss of $8.9 million, and full-year 2026 guidance. This is a standard quarterly earnings release filed under Item 2.02 with the press release attached as Exhibit 99.1, accompanied by unaudited condensed consolidated financial statements (balance sheet, statements of operations, and cash flows).","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T20:18:59.621548+00:00","company_name":"MAXCYTE, INC.","ticker":"MXCT","filing_date":"2026-08-12"},{"id":28640,"accession_number":"0001104659-26-094886","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The Item 7.01 disclosure furnishes MaxCyte's second quarter 2026 financial results press release (Exhibit 99.1), which reports total revenue of $7.3 million, net loss of $8.9 million, and full-year 2026 guidance of $30–$32 million in revenue. This is a standard quarterly earnings release with detailed financial statements and management commentary, meeting the definition of earnings_release. The material nature is confirmed by the company's reiteration of full-year guidance and discussion of strategic developments (Genentech partnership, SPL portfolio progress).","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T20:18:59.621548+00:00","company_name":"MAXCYTE, INC.","ticker":"MXCT","filing_date":"2026-08-12"}]}